Effects of Ubiquinol and/or D-Ribose in Patients With Heart Failure With Preserved Ejection Fraction
Pierce JD, Shen Q, Mahoney DE, Rahman F, Krueger KJ, Diaz FJ, Clark L, Smith C, Vacek J, Hiebert JB
Published in American Journal of Cardiology
Methodology
Randomized double-blind placebo-controlled 2x2 factorial trial of ubiquinol (200 mg/day) and/or D-ribose (15 g/day) for 12 weeks in 216 patients with heart failure with preserved ejection fraction.
Key Findings
Neither ubiquinol nor D-ribose alone significantly improved the primary symptom-burden or six-minute walk outcomes; some secondary quality-of-life measures favoured the combination.
Conclusions
D-ribose did not meaningfully reduce symptom burden in HFpEF in the largest trial to date.
Limitations
High dropout; symptom-based primary endpoints; combination effects hard to attribute.
Supplements Studied
Neither ubiquinol nor D-ribose alone significantly improved the primary symptom-burden or six-minute walk outcomes.
Outcomes Measured
D-ribose did not meaningfully reduce symptom burden in heart failure with preserved ejection fraction.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.